A phase IV, open-label, non-randomised, multi-centre study to assess the immunogenicity and safety of a booster dose of Infanrix hexa in healthy infants born to mothers vaccinated with Boostrix during pregnancy or immediately post-delivery.
Latest Information Update: 12 Dec 2022
At a glance
- Drugs Hib DTaP hepatitis B poliovirus vaccine (Infanrix hexa) (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate
- Indications Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Pneumococcal infections; Poliomyelitis; Tetanus
- Focus Pharmacodynamics
- Acronyms DTPA (BOOSTRIX)-049 BST: 048
- Sponsors GlaxoSmithKline; GSK
- 18 Feb 2021 Results of a subsequent follow-up study of our maternal immunization trial, in which we evaluated whether antibody concentrations in toddlers from Tdap-vaccinated mothers remain lower after a DTaP-HepB-IPV/Hib booster dose published in the Vaccine
- 17 May 2019 Status changed from active, no longer recruiting to completed.
- 15 Mar 2019 This study has been completed in Czech Republic.